Speaker Biographies and Information

Opening Keynote

Mariana Mazzucato, PhD, Professor in the Economics of Innovation and Public Value, University College London; Chair, WHO Council on the Economics of Health for All

Mariana Mazzucato, PhD, is Professor in the Economics of Innovation and Public Value at University College London (UCL), where she is Founding Director of the UCL Institute for Innovation & Public Purpose (IIPP). She is winner of international prizes including the Grande Ufficiale Ordine al Merito della Repubblica Italiana in 2021, Italy’s highest civilian honour, the 2020 John von Neumann Award, the 2019 All European Academies Madame de Staël Prize for Cultural Values, and 2018 Leontief Prize for Advancing the Frontiers of Economic Thought. She was named as one of the “3 most important thinkers about innovation” by The New Republic, one of the 50 most creative people in business in 2020 by Fast Company, and one of the 25 leaders shaping the future of capitalism by WIRED. She is the author of three highly-acclaimed books: The Entrepreneurial State: Debunking Public vs. Private Sector Myths (2013), The Value of Everything: Making and Taking in the Global Economy (2018) and the newly released Mission Economy: A Moonshot Guide to Changing Capitalism (2021). She advises policymakers around the world on innovation-led inclusive and sustainable growth. Her current roles include being Chair of the World Health Organization’s Economic Council on Health for All and a member of the South African President’s Economic Advisory Council, the Scottish Government’s Council of Economic Advisors, and the United Nations High-level Advisory Board (HLAB) on Economic and Social Affairs, among others.


COI: none noted

Disrupting Challenges in the Scientific Enterprise

Judy Woodruff, Anchor and Managing Editor, PBS NewsHour

Judy Woodruff, broadcast journalist, is Anchor and Managing Editor of PBS NewsHour. She has covered politics and other news for over four decades at NBC, CNN and PBS. Ms. Woodruff was the White House correspondent and then chief Washington correspondent for NBC from 1977-1983. She then joined PBS as chief Washington correspondent for MacNeil/Lehrer NewsHour and anchored PBS’ award-winning docuseries Frontline with Judy Woodruff from 1984-1990. She joined CNN in 1993 as a senior correspondent and anchor for the weekday program Inside Politics. She returned to the NewsHour in 2007. In 2013, she and the late Gwen Ifill became the first two women to co-anchor a national news broadcast. After Ifill’s death, Ms. Woodruff was named sole anchor in 2018. Ms. Woodruff is a founding co-chair of the International Women’s Media Foundation and a recipient of over 25 honorary degrees and numerous awards. Ms. Woodruff is a graduate of Duke University, where she is a trustee emerita.


COI: None noted.

Neil A. Hanchard, MD, DPhil, FACMG, Senior Investigator, Center for Precision Health Research and Head, Childhood Complex Disease Genomics Section, National Human Genome Research Institute

Neil A. Hanchard, MD, DPhil, FACMG, received his medical degree with Honours from the University of the West Indies in Kingston, Jamaica, and his DPhil in Clinical Medicine from the University of Oxford, UK, where he was a Rhodes Scholar. Thereafter he completed his clinical training as a pediatrician at the Mayo Clinic in Rochester, Minnesota and as a clinical geneticist at Baylor College of Medicine (BCM) in Houston, Texas. Dr. Hanchard is currently a Senior Investigator and Stadtman Scholar in the Center for Precision Health Research within the National Human Genome Research Institute, where he heads the Childhood Complex Disease Genomics lab. His research uses quantitative and integrative genomics to better understand the pathophysiology of complex pediatric diseases, with a particular emphasis on the interplay of population genetics and disease susceptibility in diverse populations. The lab’s current research portfolio includes studies of pediatric hypertension, transfusion reactions in sickle cell disease, severe childhood malnutrition, and pediatric HIV. Dr. Hanchard is an adjunct Associate Professor at BCM, Chair of the Genome Analysis working group of the Human Health and Heredity in Africa (H3Africa) Consortium, Chair of the Diversity Equity and Inclusion Task Force of the American Society of Human Genetics, a Member of the American Society for Clinical Investigation, and a Distinguished Scholar of the NIH.


None noted.

Dietram A. Scheufele, PhD, Taylor-Bascom Chair in Science Communication and Vilas Distinguished Achievement Professor at the University of Wisconsin-Madison and in the Morgridge Institute for Research

Dietram A. Scheufele, PhD, is the Taylor-Bascom Chair in Science Communication and Vilas Distinguished Achievement Professor at the University of Wisconsin- Madison and in the Morgridge Institute for Research, and a Distinguished Research Fellow at the University of Pennsylvania’s Annenberg Public Policy Center. Scheufele is an elected member of the American Academy of Arts and Sciences, the German National Academy of Science and Engineering, and the Wisconsin Academy of Sciences, Arts & Letters, and an elected fellow of the American Association for the Advancement of Science and the International Communication Association. He currently co-chairs the National Academy of Sciences, Engineering, and Medicine’s Standing Committee on Advancing Science Communication and the consensus study committee on Addressing Inaccurate and Misleading Information about Biological Threats. He also serves on NASEM’s Division of Behavioral and Social Sciences and Education (DBASSE) Advisory Committee, the Board on Health Sciences Policy, and the LabX Advisory Committee. Since 2012, he has co-organized five NASEM Colloquia on the Science of Science Communication. Over the course of his career, Scheufele has held fellowships or visiting appointments at Harvard, Penn, the Technische Universität Dresden, the Ludwig-Maximilians-Universität München, the Westfälische Wilhelms-Universität Münster, and–most recently–the Universität Wien. His consulting portfolio includes work for DeepMind, Porter Novelli, PBS, WHO, and the World Bank.


None noted.

Ali Shilatifard, PhD, Robert Francis Furchgott Professor Biochemistry and Pediatrics, and Director, Simpson Querrey Institute for Epigenetics, Northwestern University; Editor, Science Advances

Ali Shilatifard, PhD, is a Professor of Biochemistry and Pediatrics and the Chairman of the Department of Biochemistry and Molecular Genetics, and the Director of the Simpson Querrey Institute for Epigenetics at Northwestern University Feinberg School of Medicine. His research has been immensely focused on understanding the intricate molecular mechanisms of the regulation of gene expression. Shilatifard made a seminal contribution to the field of cancer biology by identifying the first function of any of the MLL translocation partners as an RNA Polymerase II elongation factor and linking transcription elongation control to the development of cancer. Shilatifard’s studies have remained focused over the past 25 years and have made significant inroads to understanding the cause of childhood leukemia. His studies are leading to the development of extremely promising target-specific drugs for childhood leukemia and other forms of cancer. Currently, the inhibitors towards epigenetic and transcription factors developed in Shilatifard’s laboratory such as iCOMPASS and iSEC are being tested for the treatment of childhood leukemia, brain cancer, bladder cancer, and triple-negative breast tumors. For his contributions, Shilatifard was selected as an inaugural recipient of the Outstanding Investigator Award from the National Cancer Institute, which has been supporting the research in his laboratory since 2015.  He has served as a Senior Editor for the journal Science and is the founding and current Editor for Science’s open access journal Science Advances. Shilatifard is an elected Fellow of the American Association for the Advancement of Sciences (AAAS).


COI: None noted.

Huda Y. Zoghbi, MD, Professor, Baylor College of Medicine; Investigator, Howard Hughes Medical Institute; and Director, Jan and Dan Duncan Neurological Research Institute

Huda Zoghbi, MD, is Distinguished Service Professor of Pediatrics, Molecular and Human Genetics, Neurology, and Neuroscience at Baylor College of Medicine, an Investigator with the Howard Hughes Medical Institute, and founding Director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital. Dr. Zoghbi’s expertise ranges from neurodevelopment to neurodegeneration. She and Dr. Harry Orr discovered that Spinocerebellar Ataxia type 1 is caused by expansion of a polyglutamine tract. Her subsequent studies demonstrating that such expansion leads to accumulation of the mutant protein in neurons has had profound ramifications since many late-onset neurological disorders involve similar accumulations of disease-driving proteins. Her work in neurodevelopment led to the discovery of the gene Math1/Atoh1 and showed that it governs the development of several components of the proprioceptive, balance, hearing, vestibular, and breathing pathways. She also discovered that mutations in MECP2 cause the postnatal neurological disorder Rett syndrome and revealed the importance of this gene for various neuropsychiatric features. Dr. Zoghbi has trained over 100 scientists and physician-scientists including several BRASS scholars. Dr. Zoghbi’s dedication and commitment to Baylor’s mission is palpable. She has been committed to educating the next generation of scientists and to creating collaborative opportunities. She is a member of multiple professional organizations and boards. She has been elected to the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences. Dr. Zoghbi’s honors include the Pearl Meister Greengard Prize from Rockefeller University; the Shaw Prize in Life Science and Medicine; the Breakthrough Prize in Life Sciences; the Canada Gairdner International Prize; the Victor A. McKusick Leadership Award from the American Society of Human Genetics; the Citation Laureate by Web of Science; the Lundbeck Foundation’s 2020 Brain Prize; and most recently the Kavli Foundation’s Kavli Prize and International Prize for Translational Neuroscience. She has honorary degrees from Harvard University, the University of Massachusetts, and Yale University.


Grant / Research Support – Collaborate with UCB Pharma, Belgium and Ionis Pharmaceuticals. Have institutional agreements in place at Baylor College of Medicine.

Changing the Game: Emergent Sciences and Technology

Apoorva Mandavilli, Reporter, The New York Times

Apoorva Mandavilli is a reporter for The New York Times, focusing on science and global health. She currently covers the coronavirus pandemic, the monkeypox outbreak, vaccinations, the World Health Organization and the Centers for Disease Control and Prevention. She was a part of the team that won the 2021 Pulitzer Prize for Public Service for coverage of the pandemic, and was also a member of the team that was a finalist for the 2021 Pulitzer Prize for National Reporting. She is the 2019 winner of the Victor Cohn Prize for Excellence in Medical Science Reporting, and has won numerous other awards for her writing. She is the founding editor in chief of Spectrum, an award-winning news site on autism science that grew an audience of millions. She led the team there for 13 years. She joined The Times in May 2020, after two years as a regular contributor. Her work has been published in The Atlantic, Slate and The New Yorker online, and in the anthology “Best American Science and Nature Writing.” She co-founded Culture Dish, an organization dedicated to enhancing diversity in science journalism, and was the founding chair of the Diversity Committee for the National Association of Science Writers. Ms. Mandavilli has a Master of Arts degree in journalism from New York University and a Master of Science degree in biochemistry from the University of Wisconsin-Madison. She is fluent in English, Hindi, Tamil, Telugu, and Kannada.


COI: None noted.

Kirsten Bibbins-Domingo, PhD, MD, MAS Editor-in-Chief of the Journal of the American Medical Association (JAMA) and the JAMA Network and the Lee Goldman, MD Endowed Chair and Professor of Medicine and Professor of Epidemiology and Biostatistics, University of California, San Francisco

Kirsten Bibbins-Domingo, PhD, MD, MAS, is the 17th Editor in Chief of the Journal of the American Medical Association (JAMA) and the JAMA Network. She is the Lee Goldman, MD Endowed Professor of Medicine and Professor of Epidemiology and Biostatistics at the University of California, San Francisco. Dr. Bibbins-Domingo is a general internist, cardiovascular disease epidemiologist, and a national leader in prevention and interventions to address health disparities. She is a physician-scientist who has used observational studies, pragmatic trials, and simulation modeling to examine effective clinical, public health, and policy interventions aimed at prevention. Dr. Bibbins-Domingo previously served as the inaugural Vice Dean for Population Health and Health Equity in the UCSF School of Medicine and the Chair of the Department of Epidemiology and Biostatistics at UCSF. She co-founded the UCSF Center for Vulnerable Populations at Zuckerberg San Francisco General Hospital that generates actionable research to advance health equity and reduce health disparities in the San Francisco Bay Area, California, and nationally. Dr. Bibbins-Domingo was a member of the US Preventive Services Task Force from 2010-2017 and led the Task Force as the vice-chair and chair from 2014-2017. She is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Medicine, and the American Academy of Arts and Sciences.


COI: None noted.

Karl Deisseroth, MD, PhD, D.H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences, Stanford University and Investigator, Howard Hughes Medical Institute

Karl Deisseroth, MD, PhD, is the D.H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences at Stanford University, and Investigator of the Howard Hughes Medical Institute. He received his undergraduate degree from Harvard, his PhD from Stanford, and his MD from Stanford. He also completed postdoctoral training, medical internship, and adult psychiatry residency at Stanford, and he is board-certified by the American Board of Psychiatry and Neurology. He continues as a practicing psychiatrist at Stanford with specialization in major depression and autism-spectrum disease, employing medications along with neural stimulation. His laboratory has developed optogenetics, hydrogel-tissue chemistry, and other tools for single-cell control and investigation of intact biological systems, and is known for discovering the high-resolution structural principles of light-gated ion conduction.



COI: None noted.

Bradley A. Malin, PhD, FACMI, FIAHSI, FAIMBE Professor, Biomedical Informatics, Vanderbilt University Medical Center

Bradley A. Malin, PhD, FACMI, FIAHSI, FAIMBE, is the Vice Chair for Research Affairs in the Department of Biomedical Informatics at Vanderbilt University Medical Center and the Accenture Professor of Biomedical Informatics, Biostatistics, and Computer Science at Vanderbilt University.  Dr. Malin’s research is on the development of technologies to enable artificial intelligence and machine learning (AI/ML) in the context of organizational, political, and health information architectures. He has made specific contributions in a number of areas, including algorithms to formally de-identify patient information disseminated for secondary research purposes, as well as methods to perform machine learning over electronic health records data at scale. He co-directs the Health Data Science (HEADS) Center, the Center for Genetic Privacy and Identity in Community Settings (GetPreCiSe) – an NIH Center of Excellence on Ethical, Legal, and Social Implications Research (CEER) – and the Infrastructure Core of the NIH Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity (AIM-AHEAD). In addition, he serves as the co-chair of the Committee on Access, Privacy, and Security (CAPS) of the All of Us Research Program of the U.S. Precision Medicine Initiative, an appointed member of the Technical Anonymisation Group of the European Medicines Agency, and an appointed member of the Board of Scientific Counselors of the National Center for Health Statistics of the Centers for Disease Control and Prevention (CDC). He is an elected member of the National Academy of Medicine (NAM), the American College of Medical Informatics (ACMI), the International Academy of Health Sciences Informatics (IAHSI), and the American Institute for Medical and Biological Engineering (AIMBE).


COI: None noted.

Jay Shendure, MD, PhD, Professor of Genome Sciences, University of Washington; Director, Brotman Baty Institute for Precision Medicine; and Investigator, Howard Hughes Medical Institute

Jay Shendure, MD, PhD, is an Investigator of the Howard Hughes Medical Institute, Professor of Genome Sciences at the University of Washington, Director of the Allen Discovery Center for Cell Lineage Tracing, and Scientific Director of the Brotman Baty Institute for Precision Medicine. His 2005 doctoral thesis with George Church included one of the first successful reductions to practice of next generation DNA sequencing. Dr. Shendure’s research group in Seattle pioneered exome sequencing and its earliest applications to gene discovery for Mendelian disorders and autism; cell-free DNA diagnostics for cancer and reproductive medicine; massively parallel reporter assays, saturation genome editing; whole organism lineage tracing, and massively parallel molecular profiling of single cells. Dr. Shendure is the recipient of the Curt Stern Award from the American Society of Human Genetics (2012), the Richard Lounsbery Award from the National Academy of Sciences (2019) and the Mendel Award from the European Society of Human Genetics (2022) and is an elected member of the American Association for the Advancement of Science (AAAS) and the National Academy of Sciences (NAS). He serves or has previously served as an advisor to the NIH Director, the US Precision Medicine Initiative, the National Human Genome Research Institute, the Chan-Zuckerberg Initiative and the Allen Institutes for Cell Science and Immunology. He received his MD and PhD degrees from Harvard Medical School in 2007.


COI: None noted.

Shaping the Path Forward: From Disruption to Transformation

Mariette DiChristina Professor of the Practice and Dean, College of Communication, Boston University

Mariette DiChristina is dean of Boston University’s College of Communication and a professor of the practice in journalism. Before arriving at BU in 2019, Ms. DiChristina was the first female editor-in-chief and executive vice president of Scientific American, as well as executive vice president, Magazines Division, of its publisher, Springer Nature. In that capacity, she also oversaw the journalists for the journal Nature’s magazine, as well as the Nature Research custom content and publishing groups. An elected Fellow of the American Association for the Advancement of Science, she co-chairs the Climate Communications Initiative committee for the U.S. National Academies of Science, Engineering, and Medicine; serves on the Practice and Science of Civic Science Advisory Committee for the Civic Science Fellows program; and is a member of the executive board of Society for Science, publisher of Science News. For the past several years, DiChristina has also chaired the Steering Group for the “Top 10 Emerging Technologies” for the World Economic Forum.


COI: None noted.

Sangeeta N. Bhatia, MD, PhD John J. and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science, MIT

Sangeeta N. Bhatia MD, PhD, is an inventor, Massachusetts Institute of Technology professor, and biotech entrepreneur. At MIT, she is the John J. and Dorothy Wilson Professor of Engineering, Director of the Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research, and Investigator of the Howard Hughes Medical Institute. Trained as both a physician and engineer, Dr. Bhatia’s laboratory leverages miniaturization tools from the computer industry for medical innovation with applications in liver disease, cancer and infectious diseases. She and her over 150 trainees have contributed to more than 50 issued or pending patents, launched multiple biotechnology companies to improve human health, and published more than 200 peer-reviewed papers. Dr. Bhatia was the 25th person in history to be an elected member of all three US National Academies: NAS, NAM, and NAE. She has been honored with the Lemelson-MIT Prize (known as the “Oscar” for inventors), the Heinz Medal, and the Othmer Gold Medal for groundbreaking inventions and advocacy for women in STEM fields. She has presented her vision for the application of engineering solutions to solve medical problems on international stages such as the World Economic Forum, TED, the Gates Grand Challenges, and the Biden Cancer Moonshot. She currently serves as a Trustee at Brown University and Director at Vertex Pharmaceuticals.


Grant/Research Support / Salary/Consultant Fee / Stocks/Bonds / Honorarium/Expenses – S.N.B. reports compensation for cofounding, consulting, and/or board membership in Glympse Bio, Satellite Bio, CEND Therapeutics, Catalio Capital, Intergalactic Therapeutics, Port Therapeutics, Vertex Pharmaceuticals, and Moderna, and receives sponsored research funding from Johnson & Johnson, Revitope, and Owlstone.

Elena Viboch, MS, MBA Partner, General Catalyst

Elena Viboch, MS, MBA is a Partner at General Catalyst, where she focuses on investing in life sciences. Her investments include Dewpoint Therapeutics, Eikon Therapeutics, Maze Therapeutics, Odyssey Therapeutics, Variant Bio, and Vial, and she serves on the board of Kyra.  Prior to joining General Catalyst, Ms. Viboch served as an Investment Director at SoftBank, where she helped build SoftBank Vision Fund’s healthcare portfolio, driving investments in companies such as Devoted Health and Vividion Therapeutics and serving on the boards of Deep Genomics, Karius, and Pear Therapeutics. Earlier in her career, Ms. Viboch worked in investing at Kearny Venture Partners and held operating roles at Carmot Therapeutics and NanoString. She’s passionate about working closely with rising entrepreneurs to help them bring their work from idea to execution to impact. Ms. Viboch holds a BA from Swarthmore College, an MS from Johns Hopkins University, and an MBA from Harvard Business School, where she graduated with highest honors as a Baker Scholar. Ms. Viboch lives in San Francisco, and she enjoys hiking throughout the Bay Area.

COI: None noted.

Leslie B. Vosshall, PhD Vice President and Chief Scientific Officer, Howard Hughes Medical Institute and Robin Chemers Neustein Professor and head of the Laboratory of Neurogenetics and Behavior, The Rockefeller University

Leslie B. Vosshall, PhD, is the Vice President and Chief Scientific Officer of the Howard Hughes Medical Institute, as well as HHMI Investigator and Robin Chemers Neustein Professor, Head of the Laboratory of Neurogenetics and Behavior at The Rockefeller University. She is a molecular neurobiologist known for her work on the genetic basis of chemosensory behavior in both insects and humans. Her notable contributions to science include the discovery of the insect odorant receptors, and the elucidation of general principles regarding their function, expression, and the connectivity of the sensory neurons that express them to primary processing centers in the brain. She founded The Rockefeller University Smell Study in 2004 with the goal of understanding the mechanisms by which odor stimuli are converted to olfactory percepts. Dr. Vosshall received an A.B. in biochemistry from Columbia University in 1987 and a PhD from The Rockefeller University in 1993, mentored by Michael W. Young. Following postdoctoral work with Richard Axel at Columbia University, she joined the Rockefeller faculty in 2000. She is the recipient of the 2008 Lawrence C. Katz Prize from Duke University, the 2011 Gill Young Investigator Award, the 2020 National Academy of Sciences Pradel Research Award, and the 2021 W. Alden Spencer Award (joint with Kristin Scott). Dr. Vosshall is an elected fellow of the American Association for the Advancement of Science, and a member of the National Academy of Sciences, the National Academy of Medicine, and the American Philosophical Society.


COI: None noted.

Keith R. Yamamoto, PhD Vice Chancellor for Science Policy and Strategy, UCSF, Director, UCSF Precision Medicine and Professor, Cellular & Molecular Pharmacology, University of California, San Francisco

Keith R. Yamamoto, PhD, is vice chancellor for science policy and strategy, director of precision medicine, and professor of cellular and molecular pharmacology at UCSF. After earning his PhD from Princeton University, Dr. Yamamoto joined the UCSF faculty in 1976. His research has focused on signaling and transcriptional regulation by nuclear receptors; he uses mechanistic and systems approaches to pursue these problems in pure molecules, cells and whole organisms. He has led or served on numerous national committees focused on public and scientific policy, public understanding and support of biological research, science education, and diversity, equity, inclusion and anti-racism; he is currently President Elect of the American Association for the Advancement of Science (AAAS), chairs the Coalition for the Life Sciences, co-chairs the NASEM Roundtable on Aligning Incentives for Open Science, and sits on the Board of Directors of the Public Library of Science, the Board of Directors of Rapid Science, the Governing Board of the California Institute for Regenerative Medicine, the Board of Counselors for the Radiation Effects Research Foundation, and the Advisory Board for Lawrence Berkeley National Laboratory. He has chaired or served on many committees that oversee training and the biomedical workforce, research funding, and the process of peer review and the policies that govern it at NIH. He was elected to the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Academy of Microbiology, and is a fellow of AAAS.


COI: None noted.

President’s Forum:

Transforming the Future: Perspectives from Scientific and Institutional Leaders

Victor Dzau, MD President, National Academy of Medicine

Victor J. Dzau, MD, is the President of the National Academy of Medicine (NAM), formerly the Institute of Medicine (IOM). In addition, he serves as Vice Chair of the National Research Council. Dr. Dzau is Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University and the past President and CEO of the Duke University Health System. Previously, Dr. Dzau was the Hershey Professor of Theory and Practice of Medicine and Chairman of Medicine at Harvard Medical School’s Brigham and Women’s Hospital, as well as Chairman of the Department of Medicine at Stanford University. Since arriving at the National Academies, Dr. Dzau has designed and led important initiatives such as the Commission on a Global Health Risk Framework for the Future; the Human Genome Editing Initiative; and Vital Directions for Health and Health Care. Among his many honors and recognitions are the Max Delbreck Medal from Charite, Humboldt and Max Planck, Germany, the Distinguished Scientist Award from the American Heart Association, Ellis Island Medal of Honor, and the Henry Freisen International Prize. In 2014, he received the Public Service Medal from the President of Singapore. He has been elected to the National Academy of Medicine, the American Academy of Arts and Sciences, the European Academy of Sciences and Arts, and Academia Sinica. He has received 16 honorary doctorates.


COI: none noted.

Cori Bargmann, PhD Distinguished Fellow and Head of Science Emerita, Chan Zuckerberg Initiative and head of the Lulu and Anthony Wang Laboratory of Neural Circuits and Behavior and Torsten N. Wiesel Professor, Rockefeller University

Cori Bargmann, PhD, is a neuroscientist and geneticist. She received a BS in biochemistry from the University of Georgia and a PhD from the Massachusetts Institute of Technology, where she studied the neu/HER2 oncogene with Robert A. Weinberg. Her work on the neurobiology and genetics of behavior began during a postdoctoral fellowship with H. Robert Horvitz at MIT. She has been a faculty member at the University of California, San Francisco (1991-2004) and at The Rockefeller University, as the Torsten N. Wiesel Professor and Head of the Lulu and Anthony Wang Laboratory of Neural Circuits and Behavior (2004-present). She was an HHMI Investigator from 1995-2016. Her work has addressed the relationships between genes, circuits, and behaviors in C. elegans, including the molecular basis of odor recognition and odor preference, the circuit logic and neuromodulatory systems connecting odors to behavioral responses, natural trait variation in social and foraging behaviors, and the molecules involved in nervous system wiring. She has received scientific honors including election to the National Academy of Sciences and the National Academy of Medicine, the 2012 Kavli Prize in Neuroscience and the 2013 Breakthrough Prize in Life Sciences. In 2013-2014, she co-chaired the NIH working group to the Advisory Committee to the NIH Director for President Obama’s Brain Initiative. In 2016 she became the first Head of Science at a new philanthropy, the Chan Zuckerberg Initiative, a position she held until 2022.


Grant Research Support – Chan Zuckerberg Initiative, LLC
Salary/Consultant Fees – Chan Zuckerberg Initiative, LLC

Francis Collins, MD, PhD, Senior Investigator, National Humane Genome Research Institute, and former Director, National Institutes of Health

Francis Collins, MD, PhD, currently serves as the Acting Science Advisor to President Joe Biden, steering the administration’s plans and programs to advance scientific solutions to humanity’s needs, especially for health issues. In that role, he works closely with Dr. Alondra Nelson, the Acting Director of the Office of Science Technology Policy (OSTP).  Dr. Collins also maintains his longstanding position as a Senior Investigator in the intramural program of the National Human Genome Research Institute, pursuing genomics research on type 2 diabetes and a rare disorder of premature aging called progeria. Dr. Collins previously served as the 16th Director of the National Institutes of Health (NIH), appointed by President Barack Obama and confirmed by the Senate in 2009. In 2017, President Donald Trump asked Dr. Collins to continue to serve as the NIH Director. President Joe Biden did the same in 2021. For those 12 years, serving an unprecedented three administrations, Dr. Collins oversaw the work of the largest supporter of biomedical research in the world, spanning the spectrum from basic to clinical research. Dr. Collins stepped down as Director on December 19, 2021. Dr. Collins is a physician-geneticist noted for his landmark discoveries of disease genes and his previous leadership of the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at NIH from 1993-2008. Dr. Collins is an elected member of both the National Academy of Medicine and the National Academy of Sciences, was awarded the Presidential Medal of Freedom in November 2007, and received the National Medal of Science in 2009. In 2020, he was elected as a Foreign Member of the Royal Society (UK) and was also named the 50th winner of the Templeton Prize, which celebrates scientific and spiritual curiosity.


COI: none noted

Alondra Nelson, PhD, Deputy Assistant to the President and Deputy Director for Science and Society, White House Office of Science and Technology Policy

Alondra Nelson, PhD, is the Harold F. Linder Professor at the Institute for Advanced Study. She currently serves as Deputy Assistant to the President and Deputy Director for Science and Society in the White House Office of Science and Technology Policy, where she performed the duties of the Director from February to October 2022. Dr. Nelson is most widely known for her research at the intersection of science, technology, medicine, and social inequality, and as the acclaimed author of award-winning books, including The Social Life of DNA: Race, Reparations, and Reconciliation after the Genome (2016); Body and Soul: The Black Panther Party and the Fight against Medical Discrimination (2011); Genetics and the Unsettled Past: The Collision of DNA, Race, and History (2012; with Keith Wailoo and Catherine Lee); and Technicolor: Race, Technology, and Everyday Life (2001; with Thuy Linh Tu). Before joining the Biden Administration, Nelson was co-chair of the National Academy of Medicine Committee on Emerging Science, Technology, and Innovation and was a member of the National Academy of Engineering Committee on Responsible Computing Research. She served as a past president of the Social Science Research Council, an international research nonprofit, and was previously the inaugural Dean of Social Science at Columbia University. Dr. Nelson began her academic career on the faculty of Yale University, and there was recognized with the Poorvu Prize for interdisciplinary teaching excellence. Dr. Nelson is an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, the American Association for the Advancement of Science, and the American Academy of Political and Social Science.


COI: None noted.

Marc Tessier-Lavigne, PhD, FRS, FRSC, FMedSci President, Stanford University

Marc Tessier-Lavigne, PhD, FRS, FRSC, FMedSci, pioneering neuroscientist, became Stanford University’s 11th president on September 1, 2016. He returned to Stanford after serving as president of The Rockefeller University, a graduate biomedical research university in New York City. From 2001 to 2005, he was a professor of biological sciences at Stanford, where he held the Susan B. Ford Professorship in the Humanities and Sciences. He has also held faculty positions at the University of California, San Francisco, and executive positions at biotechnology company Genentech.


COI: None noted.

Holden Thorp, PhD Editor-in-Chief, Science

Holden Thorp, PhD, became Editor-in-Chief of the Science family of journals in October 2019. He came to Science from Washington University, where he was provost from 2013 to 2019 and where he is Rita Levi-Montalcini Distinguished University Professor and holds appointments in both chemistry and medicine.  Thorp joined Washington University after spending three decades at the University of North Carolina at Chapel Hill (UNC), where he served as the 10th chancellor from 2008 through 2013.  In his research career, Thorp studied electron-transfer reactions of nucleic acids, developed technology for electronic DNA chips, and cofounded Viamet Pharmaceuticals, which developed VIVJOA (oteseconazole), now approved by the FDA and marketed by Mycovia Pharmaceuticals. Thorp is a venture partner at Hatteras Venture Partners, a consultant to Ancora, and is on the board of directors of PBS, the College Advising Corps, and Artizan Biosciences.


Salary/Consultant Fee – Ancora, Hatteras Venture Partners, Artizan Biosciences

Join Our Community

Sign up for NAM email updates